je.st
news
Tag: study results
JRC provides initial results and qualitative trends of study of regulated gaseous emissions under NEDC and new WLTP; data from 21 vehicles
2015-07-09 13:55:38| Green Car Congress
Aimmune Therapeutics Announces Positive Phase 2 Study Results Of AR101 For The Treatment Of Peanut Allergy
2015-06-17 06:39:17| foodingredientsonline Home Page
Aimmune Therapeutics, Inc., a privately held biopharmaceutical company developing desensitization treatments for food allergies, announced recently that a Phase 2 study (ARC001) evaluating the company’s lead investigational product, AR101 for the treatment of peanut allergy, met its primary endpoint and additional endpoint of desensitizing patients to cumulative amounts of peanut protein of 443 mg and 1,043 mg, respectively
Tags: of
results
study
positive
Study: Austin, Texas, Bag Ban Results in Pros, Cons
2015-06-15 21:38:00| Waste Age
A bag ban in Austin, Texas, has resulted in the reduction of the use of single-use bags, but also led to complications with an increasing number of thicker plastic bags getting into the city's recycling stream. read more
Pacritinib Phase 3 Study Shows Positive Results In Patient Reported...
2015-06-12 11:30:00| Logistics - Topix.net
As recently reported at the American Society of Clinical Oncology annual meeting, results show a significant reduction in the Total Symptom Score , and in each individual common disease-related symptom, from baseline to Week 24, in patients treated with pacritinib compared to best available therapy . These PROs, as well as other quality of life measures, will be presented at the 20th Congress of European Hematology Association by .
Tags: results
study
shows
positive
Results from Investigational IMPROVE-IT Study of VYTORIN (ezetimibe and simvastatin) Published in the New England Journal of Medicine
2015-06-03 23:00:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the New England Journal of Medicine published the results of the IMPROVE-IT trial, an investigational study comparing treatment with VYTORIN (ezetimibe and simvastatin) to treatment with simvastatin alone in more than 18,000 patients presenting with acute coronary syndromes. Language: English Contact: MerckMedia:Pamela Eisele, (267) 305-3558Tracy Ogden, (267) 305-2301orInvestor:Justin Holko, (908) 740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: of
results
study
journal